Acumen Pharmaceuticals Inc.

1.73
-0.02 (-1.14%)
Jan 23, 2025, 3:13 PM - Market open
-1.14%
Bid 1.72
Market Cap 103.64M
Revenue (ttm) 290.00K
Net Income (ttm) -81.67M
EPS (ttm) -1.38
PE Ratio (ttm) -1.25
Forward PE -1.75
Analyst Buy
Ask 1.73
Volume 261,577
Avg. Volume (20D) 312,566
Open 1.72
Previous Close 1.75
Day's Range 1.67 - 1.77
52-Week Range 1.53 - 5.09
Beta 0.04

About ABOS

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia....

Industry Biotechnology
Sector Healthcare
IPO Date Jul 1, 2021
Employees 51
Stock Exchange NASDAQ
Ticker Symbol ABOS

Analyst Forecast

According to 3 analyst ratings, the average rating for ABOS stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 305.80% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
5 months ago
-9.03%
Acumen Pharmaceuticals shares are trading lower. T... Unlock content with Pro Subscription
10 months ago
-11.76%
Acumen Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 EPS results.